Citius Pharma Reports Q2 Revenue, Secures $26.5M+ Financing, Extends Runway

summarizeSummary

Citius Pharmaceuticals reported Q2 FY2026 results with $1.7 million in product revenue and announced securing over $26.5 million in new financing, extending its cash runway through November 2026.

check_boxKey Events

• Q2 FY2026 Financial Results

  Reported $1.7 million in net product revenue from LYMPHIR, with an 80% gross margin. The net loss was $21.2 million, or $(0.95) per share.

• Significant Financing Secured

  Citius Pharma completed a $5 million registered direct offering. Its subsidiary, Citius Oncology, secured an additional $11.5 million from warrant exercises and an initial $10 million from a $25 million debt facility, totaling over $26.5 million in new capital.

• Cash Runway Extended

  The combined financing is expected to fund operations through November 2026, addressing immediate liquidity concerns highlighted by a prior going concern warning.

• LYMPHIR Commercial Progress

  The company reported strong early commercial momentum for LYMPHIR, with 83% of target accounts on formulary review and near 100% payer coverage. Initial shipments to Europe have also commenced.

auto_awesomeAnalysis

Citius Pharmaceuticals reported its Q2 FY2026 results, marking initial product revenue of $1.7 million from its LYMPHIR launch. Crucially, the company and its subsidiary Citius Oncology secured over $26.5 million in new financing, including a $5 million registered direct offering, $11.5 million from warrant exercises, and an initial $10 million from a debt facility. This capital infusion extends the company's cash runway through November 2026, providing critical liquidity given its prior going concern warning. The reported net loss of $21.2 million for the quarter was significantly impacted by a $19.7 million one-time contract cancellation charge.